Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07754461

PHASE3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine. Depending on a person's diabetes treatment, a person will be assigned either to * Part A: healthy eating and physical activity * Part B: diabetes tablets (no injection of insulin) * Part C: injection of insulin (with or without diabetes tablets) Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment. Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.

Official title: A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

600

Start Date

2026-08-24

Completion Date

2028-05-01

Last Updated

2026-09-03

Healthy Volunteers

Conditions

Type 2 Diabetes

Interventions

DRUG

Placebo

DRUG

Survodutide

Inclusion criteria: 1. Male or female, age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is \>18 years 2. Diagnosed with type 2 diabetes mellitus (T2D) (e.g. American diabetes association (ADA)/European association for the study of diabetes (EASD) guidelines) and must meet requirements for one of background therapy parts A, B or C: 1. Part A: Naïve to insulin therapy and have not used oral or injectable anti-hyperglycaemic (diabetes) medication for at least 90 days prior to screening (Visit 1) and glycosylated haemoglobin A1c (HbA1c) ≥7.0 (≥53 mmol/mol) and \<9.5% (\<80 mmol/mol) as measured by the central laboratory at screening (Visit 1); 2. Part B: Treated with stable dose of oral antidiabetic medication (OAD) for 90 days prior to screening (Visit 1) as monotherapy or combination of: Maximum tolerated dose of metformin and/or Maximum tolerated dose of sulfonylurea and/or Maximum tolerated dose of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and HbA1c ≥7.0% (≥53 mmol/mol) and \<10.5% (\<91 mmol/mol) as measured by the central laboratory at screening (Visit 1); 3. Part C: Stable use of basal insulin at a dose of ≥20 international units (IU)/day with or without stable dose of metformin and/or SGLT2i for 90 days prior to screening (Visit 1) and HbA1c ≥7.0% (≥53 mmol/mol) and \<10.5% (\<91 mmol/mol) as measured by the central laboratory at screening (Visit 1) 3. Body mass index (BMI) ≥23 kg/m2 at screening (Visit 1) 4. Signed and dated written informed consent in accordance with international council for harmonisation - good clinical practice (ICH-GCP) and local legislation prior to admission to the trial 5. Woman (or women) of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per international council for harmonisation of technical requirements for pharmaceuticals for human use M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. 6. In the investigator's opinion, participants are well-motivated, capable, and willing to: Learn how to self-inject the investigational medicinal product (IMP), as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP); Inject the IMP or accept injection from a designated person; Follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise plan), maintain a diary, complete required questionnaires, and handle the IMP as described in the instructions for use (IFU) Exclusion criteria: 1. Type 1 diabetes mellitus (T1D) or latent autoimmune diabetes in adults (LADA) 2. Treatment within 90 days before screening (Visit 1) up to and including randomisation (Visit 2) with any: glucagon-like peptide-1 receptor (GLP-1R) agonists including GLP-1R agonist/glucose-dependent insulinotropic polypeptide (GIP) combinations, amylin or incretin combinations; Glucose-lowering drugs other than stated in the inclusion criteria for each part (i.e. metformin, Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i), basal insulin, depending on the background therapy part); Glucose-lowering investigational drug; Any anti-obesity medication including bupropion/naltrexone, orlistat, phentermine, and phentermine/topiramate 3. History of ketoacidosis or hyperosmolar state or coma within the last 6 months before screening (Visit 1) up to and including randomisation (Visit 2) 4. Hypoglycaemia unawareness or a history of severe hypoglycaemia within the last 3 months before screening (Visit 1) up to and including randomisation (Visit 2) 5. Diabetic retinopathy or maculopathy currently under treatment, or that is reasonably anticipated to require such treatment over the duration of the study 6. Body weight change (self-reported) \>5% within 90 days before screening (Visit 1) 7. Previous or planned (during the trial period) treatment for obesity with surgery or a weight loss device, including any prior bariatric surgery. The following are allowed: (1) liposuction and/or abdominoplasty, if performed \>1 year before screening (Visit 1), (2) lap banding, if the band has been removed \>1 year before screening (Visit 1), (3) intragastric balloon, if the balloon has been removed \>1 year before screening (Visit 1), (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \>1 year before screening (Visit 1). 8. Answered "yes" to any of the suicide-related behaviours (Actual attempt, Interrupted attempt, Aborted attempt, Preparatory act or behaviour) or to the non-suicidal self-injurious behaviour question on the "Suicidal Behaviour" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) related to the past 2 years before screening (Visit 1) up to and including randomisation (Visit 2) 9. Further exclusion criteria apply.

Locations (121)

Cahaba Research, Inc. - Trussville Location

Birmingham, Alabama, United States

Mission Research Institute - Gilbert

Gilbert, Arizona, United States

Helios Clinical Research - Paradise Valley

Paradise Valley, Arizona, United States

Arizona Liver Health - Peoria 85381

Peoria, Arizona, United States

Helios Clinical Research - Phoenix

Phoenix, Arizona, United States

Woodland International Research Group, Inc.

Little Rock, Arkansas, United States

San Fernando Valley Health

Canoga Park, California, United States

John Muir Physician Network Clinical Research Center

Concord, California, United States

Neighborhood Healthcare - Escondido

Escondido, California, United States

Clinical Trials Research - Lincoln

Lincoln, California, United States

ARK Clinical Research

Long Beach, California, United States

Infinity Clinical Research

Norco, California, United States

Valley Clinical Trials, Inc.

Northridge, California, United States

Fomat Medical Research

Oxnard, California, United States

Encompass Clinical Research, Spring Valley

Spring Valley, California, United States

University Clinical Investigators, Inc.

Tustin, California, United States

Diablo Clinical Research

Walnut Creek, California, United States

Focus Clinical Research

West Hills, California, United States

Clinical Research of West Florida, Inc.

Clearwater, Florida, United States

Northeast Research Institute

Fleming Island, Florida, United States

Covenant Metabolic Specialists, LLC - Fort Myers

Fort Myers, Florida, United States

Encore Medical Research

Hollywood, Florida, United States

Northeast Research Institute

Jacksonville, Florida, United States

Accel Research Sites - Lakeland

Lakeland, Florida, United States

Clinical Research of Central Florida - Lakeland

Lakeland, Florida, United States

Tampa Bay Medical Research - Largo

Largo, Florida, United States

New Horizon Research Center-Miami-69732

Miami, Florida, United States

South Broward Research

Miramar, Florida, United States

Covenant Metabolic Specialists, LLC - Brandon

Riverview, Florida, United States

Covenant Metabolic Specialists, LLC - Sarasota

University Park, Florida, United States

Metabolic Research Institute, Inc.

West Palm Beach, Florida, United States

Encore Medical Research - Weston

Weston, Florida, United States

Conquest Research

Winter Park, Florida, United States

Centricity Research, Endocrine Consultants

Columbus, Georgia, United States

Javara-Fayetteville-67354

Fayetteville, Georgia, United States

Balanced Life Health Care Solutions

Lawrenceville, Georgia, United States

Rophe Adult and Pediatric Medicine

Union City, Georgia, United States

Pacific Diabetes & Endocrine Center

Honolulu, Hawaii, United States

Elite Clinical Trials - Blackfoot

Blackfoot, Idaho, United States

Family First Clinical Research

Idaho Falls, Idaho, United States

Solaris Clinical Research

Meridian, Idaho, United States

Evanston Premier Healthcare Research LLC

Skokie, Illinois, United States

Cotton O'Neil Mulvane

Topeka, Kansas, United States

AMR Lexington

Lexington, Kentucky, United States

Endocrine and Metabolic Consultants

Rockville, Maryland, United States

Northern Pines Health Center - Buckley

Buckley, Michigan, United States

Revival Research Institute, LLC - Dearborn

Dearborn, Michigan, United States

Arcturus Healthcare - Troy Internal Medicine Research Division

Troy, Michigan, United States

International Diabetes Center

Minneapolis, Minnesota, United States

Olive Branch Family Medical Center

Olive Branch, Mississippi, United States

SKY Clinical Research Network Group - Ridgeland

Ridgeland, Mississippi, United States

StudyMetrix Research, LLC

City of Saint Peters, Missouri, United States

Logan Health Research - Kalispell

Kalispell, Montana, United States

Boeson Research - Missoula

Missoula, Montana, United States

Palm Research Center

Las Vegas, Nevada, United States

Albuquerque Clinical Trials

Albuquerque, New Mexico, United States

Ellipsis Research Group - Brooklyn

Brooklyn, New York, United States

Cape Fear Valley Medical Center

Fayetteville, North Carolina, United States

PharmQuest Life Sciences

Greensboro, North Carolina, United States

Centricity Research - Morehead City

Morehead City, North Carolina, United States

Diabetes & Endocrinology Associates of Stark County

Canton, Ohio, United States

Advanced Medical Research - Maumee

Maumee, Ohio, United States

New Venture Medical Research

Wadsworth, Ohio, United States

Tekton Research-Edmond-68875

Edmond, Oklahoma, United States

Heritage Valley Medical Group

Beaver, Pennsylvania, United States

Preferred Primary Care Physicians-Pittsburgh-63932

Pittsburgh, Pennsylvania, United States

Preferred Primary Care Physicians

Pittsburgh, Pennsylvania, United States

Preferred Primary Care Physicians - Matthew Drive

Uniontown, Pennsylvania, United States

PanAmerican Clinical Research - Bluffton

Bluffton, South Carolina, United States

Spartanburg Medical Research

Spartanburg, South Carolina, United States

University Diabetes & Endocrine Consultants

Chattanooga, Tennessee, United States

LifeDoc Research, PLLC

Memphis, Tennessee, United States

Texas Diabetes and Endocrinology

Austin, Texas, United States

South Texas Research Institute - Brownsville

Brownsville, Texas, United States

Privia Medical Group Gulf Coast, PLLC

Conroe, Texas, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Pinnacle Clinical Research - Georgetown

Georgetown, Texas, United States

Juno Research, LLC

Houston, Texas, United States

Biopharma Informatic, Inc. Research Center

Houston, Texas, United States

Research Physicians Network

Houston, Texas, United States

Southern Endocrinology Associates

Mesquite, Texas, United States

Pinnacle Clinical Research - San Antonio

San Antonio, Texas, United States

Pinnacle Clinical Research, LLC

San Antonio, Texas, United States

Consano Clinical Research

Shavano Park, Texas, United States

Texas Valley Clinical Research

Weslaco, Texas, United States

Olympus Family Medicine

Salt Lake City, Utah, United States

Tidewater Physicians Multispecialty Group

Newport News, Virginia, United States

ERA Health Research - Redmond

Redmond, Washington, United States

Clinical Investigation Specialists, Inc.-Kenosha-69111

Kenosha, Wisconsin, United States

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Logan Hospital

Meadowbrook, Queensland, Australia

Southern Adelaide Diabetes & Endocrine services

Oaklands Park, South Australia, Australia

Baker Heart and Diabetes Institute

Melbourne, Victoria, Australia

Fraser Clinical Trials

New Westminster, British Columbia, Canada

Centricity Research (Brampton)

Brampton, Ontario, Canada

Centricity Research (Vaughan)

Concord, Ontario, Canada

Centricity Research (Nepean)

Nepean, Ontario, Canada

Centricity Research (Bayview)

Toronto, Ontario, Canada

Diabetes Heart Research Centre

Toronto, Ontario, Canada

Albion Finch Medical Centre

Toronto, Ontario, Canada

Applied Medical Informatics Research Inc.

Montreal, Quebec, Canada

Endocrinologie Oasis Inc

Montreal, Quebec, Canada

Recherche Clinique Sigma Inc.

Québec, Canada

Gujarat Endocrine Centre

Ahmedabad, India

Sardar Vallabhbhai Patel Institute of Medical Sciences and Research

Ahmedabad, India

AIIMS Bhubaneshwar

Bhubaneswar, India

S.C.B. Medical College & Hospital

Cuttack, India

Osmania Medical College & Hospital

Hyderabad, Afzalgunj, India

Shree Mahalaxmi Diatone Institute

Kolhāpur, India

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Lucknow, India

Diabetes Care and Research Centre

Nagpur, India

Supe Heart & Diabetes Hospital & Research Centre

Nashik, India

AIIMS, New Delhi

New Delhi, India

Deenanath Mangeshkar Hospital and Research Centre

Pune, India

Jothydev's Diabetes Research Centre

Trivandrum, India

Vishakha Institute of Medical Sciences

Visakhapatnam, India

New Zealand Clinical Research (NZCR) Christchurch

Christchurch Central City, Christchurch, New Zealand

Momentum Clinical Research Dunedin

Central Dunedin, Dunedin, New Zealand

Waitemata Clinical Research

Auckland, New Zealand

Clinical Trials New Zealand Ltd

Hamilton, New Zealand

Isis Clinical Research Center

Guaynabo, Puerto Rico

Clinical Research Directory

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (121)